PARMAX

The stock has been placed in Graded Surveillance Measure (GSM) list GSM - 0.

Parmax Pharma Ltd.

BSE: 540359

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

106.75+2.1 (+1.96%)

7 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

Score not available

Value Score

Score not available

Price Momentum Score

Score not available

QVM Score

Score not available

Key Metrics

Market Cap

39.94

P/E (TTM)

P/B

P/S (TTM)

3.30

EV/EBITDA

CAPE (5Y)

ROE (TTM)

ROCE (TTM)

-81.12

ROA (TTM)

-17.77

Avg 3Y ROE

Earnings 3Y CAGR

-241.18

Sales 3Y CAGR

-7.74

Sales 5Y CAGR

Debt/Equity

Consensus TP

Strong Buy %

Promoter Holding

30.80

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Parmax Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Not enough talking points with positive stance

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of -10.41% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Parmax Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Parmax Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Parmax Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.83	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80
Indian Promoter	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.83	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80	30.80
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.17	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20	69.20
Bodies Corporate	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.07	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.11	0.11	0.11	0.10	0.10	0.10	0.10	0.16
Others (incl. Retail) No. of shareholders	69.16 785	69.16 824	69.16 858	69.16 890	69.16 923	69.16 1,181	69.16 1,337	69.13 1,519	69.16 1,545	69.16 1,584	69.16 1,01,644	69.16 2,029	69.16 1,991	69.16 1,972	69.16 1,967	69.16 1,996	69.13 2,094	69.16 2,179	69.09 2,239	69.09 2,327	69.09 2,349	69.10 2,371	69.10 2,392	69.10 2,386	69.10 2,380	69.04 2,263

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Parmax Pharma Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
GOSALIA MEENA ALKESH Directors Immediate Relative	April-2022	Inter-se Transfer (Acquisition) 19th Apr 2022	4.54 %	₹ 0.00	2.55 lac	₹ 0.00

No corporate action data available.

Company Profile

Overview of Parmax Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Parmax Pharma Ltd is an India-based company, which is engaged in active pharmaceutical ingredients (API) and contract manufacturing operations (CMO) business. It uses quality by design techniques to produce complex molecules enabling customers to create formulations. The Company’s manufacturing unit...

Key personnel

Mr. Keyur D. Vora

Chief Financial Officer

Ms. Bhakti R. Aghera

Compliance Officer, Company Secretary

Dr. Umang Alkesh GosaliaD

Managing Director, Executive Director

Ms. Ami Rajeshbhai ShahD

Non-Executive Independent Director

Mr. Nikhil S. UchatD

Non-Executive Independent Director

Incorporated on

02 Nov 1994

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

16 Mar 2017

Free Float

17,35,571

Website

https://www.parmaxpharma.com/

Phone no.

+912827270534

Address

PLOT NO 20, SURVEY NO 52, NH 8-B, HADAMTALA, RAJKOT, , 360311, India

Frequently Asked Questions

What is the current share price of Parmax Pharma Ltd.?

The current share price of Parmax Pharma Ltd. is ₹ 106.75 as of 7 Aug 2026.

What is the market capitalisation of Parmax Pharma Ltd.?

The market capitalisation of Parmax Pharma Ltd. stands at ₹ 39.94 Cr.

What is the PE ratio of Parmax Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Parmax Pharma Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Parmax Pharma Ltd.?

Parmax Pharma Ltd. has a Return on Equity (ROE) of - and a Return on Capital Employed (ROCE) of -81.12% as per the latest financial reports.

What is the 52-week high and low of Parmax Pharma Ltd.?

The 52-week high of Parmax Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Parmax Pharma Ltd.?

The dividend yield of Parmax Pharma Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Parmax Pharma Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 69.04% of Parmax Pharma Ltd. shares.

What sector does Parmax Pharma Ltd. belong to?

Parmax Pharma Ltd. operates in the Healthcare sector.

What is the beta of Parmax Pharma Ltd.?

The beta of Parmax Pharma Ltd. is 0.11, indicating its price volatility relative to the broader market. Over the past 1 year, Parmax Pharma Ltd. has delivered an absolute return of 170.32%.

What is the RSI of Parmax Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Parmax Pharma Ltd. is 70.03, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Parmax Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Parmax Pharma Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Company Profile

Stock Analysis